EYPT Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -6183.44% compared to EyePoint Pharmaceuticals, Inc.'s net margin of -82.06%. EyePoint Pharmaceuticals, Inc.'s return on equity of -79.15% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

EyePoint Pharmaceuticals, Inc. has a consensus price target of $35.50, signalling upside risk potential of 112.32%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.47%. Given that EyePoint Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe EyePoint Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

EyePoint Pharmaceuticals, Inc. has a beta of 1.668, which suggesting that the stock is 66.808% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

EyePoint Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals, Inc. quarterly revenues are $966K, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. EyePoint Pharmaceuticals, Inc.'s net income of -$59.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, EyePoint Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals, Inc. is 27.09x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -6183.44% compared to EyePoint Pharmaceuticals, Inc.'s net margin of -255.85%. EyePoint Pharmaceuticals, Inc.'s return on equity of -79.15% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

EyePoint Pharmaceuticals, Inc. has a consensus price target of $35.50, signalling upside risk potential of 112.32%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that EyePoint Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe EyePoint Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

EyePoint Pharmaceuticals, Inc. has a beta of 1.668, which suggesting that the stock is 66.808% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

EyePoint Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. EyePoint Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals, Inc. quarterly revenues are $966K, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. EyePoint Pharmaceuticals, Inc.'s net income of -$59.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, EyePoint Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals, Inc. is 27.09x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -6183.44% compared to EyePoint Pharmaceuticals, Inc.'s net margin of --. EyePoint Pharmaceuticals, Inc.'s return on equity of -79.15% beat Palatin Technologies's return on equity of --.

EyePoint Pharmaceuticals, Inc. has a consensus price target of $35.50, signalling upside risk potential of 112.32%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than EyePoint Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than EyePoint Pharmaceuticals, Inc..

EyePoint Pharmaceuticals, Inc. has a beta of 1.668, which suggesting that the stock is 66.808% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

EyePoint Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals, Inc. quarterly revenues are $966K, which are larger than Palatin Technologies quarterly revenues of --. EyePoint Pharmaceuticals, Inc.'s net income of -$59.7M is higher than Palatin Technologies's net income of --. Notably, EyePoint Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals, Inc. is 27.09x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -6183.44% compared to EyePoint Pharmaceuticals, Inc.'s net margin of --. EyePoint Pharmaceuticals, Inc.'s return on equity of -79.15% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

EyePoint Pharmaceuticals, Inc. has a consensus price target of $35.50, signalling upside risk potential of 112.32%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 142.13%. Given that Viking Therapeutics, Inc. has higher upside potential than EyePoint Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than EyePoint Pharmaceuticals, Inc..

EyePoint Pharmaceuticals, Inc. has a beta of 1.668, which suggesting that the stock is 66.808% more volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

EyePoint Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals, Inc. quarterly revenues are $966K, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. EyePoint Pharmaceuticals, Inc.'s net income of -$59.7M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, EyePoint Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals, Inc. is 27.09x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.